ArriVent BioPharma (NASDAQ:AVBP) Rating Lowered to Strong Sell at Wall Street Zen

ArriVent BioPharma (NASDAQ:AVBP) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently weighed in on AVBP. Jefferies Financial Group set a $18.00 target price on ArriVent BioPharma in a report on Tuesday, October 6th. JonesTrading dropped their price target on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. BTIG Research dropped their price target on ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday. Guggenheim cut their price objective on ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ArriVent BioPharma in a research note on Tuesday, September 22nd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, ArriVent BioPharma presently has a consensus rating of “Moderate Buy” and an average target price of $27.44.

ArriVent BioPharma Price Performance

Shares of AVBP opened at $16.73 on Friday. The firm has a market cap of $824.96 million, a PE ratio of -4.62 and a beta of 1.34. The company’s fifty day moving average is $28.76 and its two-hundred day moving average is $29.31. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.06). As a group, equities research analysts anticipate that ArriVent BioPharma will post -4.05 earnings per share for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new position in shares of ArriVent BioPharma during the 2nd quarter valued at $59,000. Jupiter Topco LLC purchased a new stake in ArriVent BioPharma during the 2nd quarter worth $226,000. Arizona State Retirement System purchased a new stake in ArriVent BioPharma during the 2nd quarter worth $233,000. Glenmede Trust Co. NA purchased a new stake in ArriVent BioPharma during the 1st quarter worth $209,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in ArriVent BioPharma in the 1st quarter valued at $209,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

More ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $4.06 from a loss of $4.14 and improved its estimates for several upcoming quarters. The firm also increased its FY2027 forecast to a loss of $3.97 from $4.24, suggesting it expects ArriVent’s losses to be somewhat narrower than previously projected. HC Wainwright maintained its Buy rating. ArriVent BioPharma Stock Price Target Cut by HC Wainwright
• Neutral Sentiment: The revised forecasts still call for substantial losses, including estimated quarterly losses of approximately $0.96 to $1.02 per share through 2027. The changes primarily reflect updated expectations rather than a new clinical, regulatory or commercial catalyst.
• Negative Sentiment: HC Wainwright reduced its price target to $27, despite retaining its Buy rating. A target reduction can weigh on sentiment because it signals less upside than previously anticipated, even though the target remains above the current trading level. ArriVent BioPharma Stock Price Target Cut by HC Wainwright
• Negative Sentiment: Wall Street Zen separately lowered its rating on ArriVent BioPharma, adding to the cautious tone surrounding the stock. The specific revised rating and rationale were not provided in the available report. ArriVent BioPharma Stock Rating Lowered by Wall Street Zen

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.